These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 33910273)

  • 1. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
    Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of PD-L1 expression in combination with CD8
    Yang H; Shi J; Lin D; Li X; Zhao C; Wang Q; Zhang L; Jiang T; Zhao S; Liu X; Jia Y; Zhang Y; Cai W; Zhou C
    Cancer Med; 2018 Jan; 7(1):32-45. PubMed ID: 29168339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions.
    Teng F; Meng X; Wang X; Yuan J; Liu S; Mu D; Zhu H; Kong L; Yu J
    Oncotarget; 2016 Sep; 7(39):64318-64329. PubMed ID: 27602763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic biomarker tumor-infiltrating lymphocytes failed to serve as a predictive biomarker for postoperative radiotherapy in completely resected pN2 non-small cell lung cancer: a retrospective analysis.
    Li J; Li L; Wang J; Liu N; Liu H; Xu F; Li M; Yuan S
    Respir Res; 2024 Jun; 25(1):244. PubMed ID: 38886760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.
    Parra ER; Behrens C; Rodriguez-Canales J; Lin H; Mino B; Blando J; Zhang J; Gibbons DL; Heymach JV; Sepesi B; Swisher SG; Weissferdt A; Kalhor N; Izzo J; Kadara H; Moran C; Lee JJ; Wistuba II
    Clin Cancer Res; 2016 Dec; 22(24):6278-6289. PubMed ID: 27252415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival.
    Kilvaer TK; Paulsen EE; Khanehkenari MR; Al-Saad S; Johansen RM; Al-Shibli K; Bremnes RM; Busund LT; Donnem T
    Br J Cancer; 2016 May; 114(10):1145-51. PubMed ID: 27167450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
    Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
    Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent expression of CD45RO memory T cell marker as well as low to high expression of PD-1 and PD-L1 inhibitory molecules in seminoma and dysgerminoma.
    Farahani H; Dehghanian AR; Khademolhosseini A; Haghshenas MR; Erfani N
    J Reprod Immunol; 2024 Feb; 161():104184. PubMed ID: 38171036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative prognostic behaviour of PD-L1 expression in tongue and larynx squamous cell carcinoma and its significant predictive power in combination with PD-1 expression on TILs.
    Ahmadvand S; Norouzi LA; Mohammadi Y; Safaei A; Khademi B; Motiee-Langroudi M; Ghaderi A
    BMC Immunol; 2024 Jan; 25(1):7. PubMed ID: 38229027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma.
    Chen X; Chen H; Lin R; Li Y; Guo Y; Chen Q; Zhang Y; Cai G; Hu M; Chen G
    J Clin Pathol; 2023 Dec; 77(1):61-67. PubMed ID: 36319076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implications of STK11 with different mutation status and its relationship with tumor-infiltrating immune cells in non-small cell lung cancer.
    Zheng J; Deng Y; Huang B; Chen X
    Front Immunol; 2024; 15():1387896. PubMed ID: 38736875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.
    Mu CY; Huang JA; Chen Y; Chen C; Zhang XG
    Med Oncol; 2011 Sep; 28(3):682-8. PubMed ID: 20373055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study.
    Chen YB; Mu CY; Huang JA
    Tumori; 2012 Nov; 98(6):751-5. PubMed ID: 23389362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer.
    Lopez de Rodas M; Nagineni V; Ravi A; Datar IJ; Mino-Kenudson M; Corredor G; Barrera C; Behlman L; Rimm DL; Herbst RS; Madabhushi A; Riess JW; Velcheti V; Hellmann MD; Gainor J; Schalper KA
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35649657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    Nagasaki Y; Taki T; Nomura K; Tane K; Miyoshi T; Samejima J; Aokage K; Ohtani-Kim SJ; Kojima M; Sakashita S; Sakamoto N; Ishikawa S; Suzuki K; Tsuboi M; Ishii G
    J Natl Cancer Inst; 2024 Jul; 116(7):1158-1168. PubMed ID: 38459590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of programmed cell death ligand 1 (PD-L1) expression in patients with stage III non-small cell lung cancer under different treatment types: a retrospective study.
    Castro NM; Moura F; Hada AL; Garcia D; Victor EDS; Schvartsman G; Carvalho L; Fernandes MLC; Martins RS; Silva EFD; Santos SSMBD; Taniwaki L; Taranto P; Pontes J; Beal JR; Dutra ACP; Oliveira Filho JB; Araujo SEA; Usón Junior PLS
    Einstein (Sao Paulo); 2024; 22():eAO0575. PubMed ID: 38922219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer.
    Okuma Y; Hishima T; Kashima J; Homma S
    Cancer Immunol Immunother; 2018 Mar; 67(3):495-505. PubMed ID: 29243049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.
    Kiryu S; Ito Z; Suka M; Bito T; Kan S; Uchiyama K; Saruta M; Hata T; Takano Y; Fujioka S; Misawa T; Yamauchi T; Yanagisawa H; Sato N; Ohkusa T; Sugiyama H; Koido S
    BMC Cancer; 2021 Nov; 21(1):1197. PubMed ID: 34758773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.